Clinical trial
A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
NCT02316106 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 20, 2015
- Completion date
- June 3, 2024
- Enrollment
- 123 (actual)
- Sites
- 57
Conditions
As the registry lists them; a condition with its own page is linked.